# Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

> **NCT02401503** · PHASE2 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 66 (actual)

## Conditions studied

- Chronic Lymphocytic Leucemia

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** GA101
- **DRUG:** ABT-199

## Key facts

- **NCT ID:** NCT02401503
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-06
- **Primary completion:** 2024-12-10
- **Final completion:** 2024-12-17
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02401503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02401503, "Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02401503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*